NCT06194214View on ClinicalTrials.gov

A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Digoxin (P-Glycoprotein Substrate) in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 11, 2021

Primary Completion Date

June 9, 2021

Study Completion Date

June 9, 2021

Conditions
Healthy
Interventions
DRUG

Pirtobrutinib

Administered Orally.

DRUG

Digoxin

Administered Orally.

Trial Locations (1)

53704

Covance Clinical Research Unit, Madison

Sponsors

Collaborators (1)

Loxo Oncology, Inc.
All Listed Sponsors
collaborator

Loxo Oncology, Inc.

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY

NCT06194214 - A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Digoxin (P-Glycoprotein Substrate) in Healthy Participants | Biotech Hunter | Biotech Hunter